Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Kína2. fázis

Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial

A legfontosabb adatok

Ki végzi
Institute of Hematology & Blood Diseases Hospital, China
Hol
Tianjin (Kína)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
129 fő, tervezett
Kezdés
2025. máj. 22.
Várható befejezés
2028. aug. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Romiplostim N01 combined with dexamethasone
  • Dexamethasone monotherapy
A regiszteradat frissítve
2025. május 28.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults newly diagnosed with primary immune thrombocytopenia (ITP), a low platelet count caused by the immune system, who have not been treated yet. It compares romiplostim N01 plus dexamethasone with dexamethasone alone.

Életkor
18 to 75 years
Nem
All sexes
A betegség stádiuma
Primary ITP diagnosed less than 3 months before randomization. ECOG PS score 0 - 2, meaning able to care for yourself. Expected survival of at least 12 weeks.
Korábbi kezelés
No earlier treatment for ITP, including emergency treatment. No earlier romiplostim. No spleen removal. No c-Mpl stimulating drugs or blood growth factors within 4 weeks. No antibody drugs such as rituximab within 14 weeks. No herbal or supplement products to raise platelets within 1 week.
Biomarker vagy leletérték
Platelet value < 30×10^9/L

A részvétel fő kizáró okai

  • Low platelets from another cause, such as leukemia, cancer treatment, inherited disease or autoimmune disease like lupus
  • Past blood clots in arteries or veins, or use of blood thinners or antiplatelet drugs
  • Severe heart disease, such as grade III/IV heart failure or past stent or bypass
  • Positive HIV or syphilis test, or active hepatitis B or C
  • Pregnant, breastfeeding or planning a pregnancy

A regiszter feltételei, szó szerint

Mind a 27 feltétel megnézéseKevesebb

Ki vehet részt

  • Sign the written informed consent form before enrollment
  • Age ranging from 18 to 75 years old
  • Be clinically diagnosed with primary immune thrombocytopenia for less than 3 months before randomization
  • have not received any prior treatments for ITP
  • Have not received romiplostim treatment
  • ECOG PS score: 0 - 2
  • Platelet value < 30×10\^9/L
  • The expected survival period at the screening is ≥ 12 weeks
  • For subjects of reproductive age, agree to take reliable contraceptive measures throughout the study period (including male or female condoms, contraceptive foams, contraceptive gels, contraceptive membranes, contraceptive ointments, contraceptive suppositories, abstinence, and intrauterine device placement, etc.); Female subjects who have undergone hysterectomy, bilateral salpingectomy, bilateral tubal ligation or menopause for more than 1 year, and male subjects who have undergone bilateral vasectomy or ligation are excluded
  • Voluntarily join this study, sign the informed consent form, and have good compliance

Ki nem vehet részt

  • Having received ITP drug treatment (including emergency treatment) before the first administration
  • Having used drugs with c-Mpl (thrombopoietin receptor) stimulating effects within 4 weeks before the first administration
  • Having received hematopoietic growth factor preparations (such as granulocyte colony-stimulating factor, macrophage colony-stimulating factor, erythropoietin, interleukin-11, etc.) within 4 weeks before the first administration
  • Having received antibody drugs (such as rituximab, etc.) within 14 weeks before the first administration
  • Having participated in other clinical studies within 3 months before the first administration
  • Suffering from other secondary thrombocytopenia except ITP, including but not limited to leukemia, thrombocytopenia caused by tumor treatment, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome, common variable immunodeficiency, and hereditary thrombocytopenia, etc
  • Having been diagnosed with arterial thrombosis (such as cerebral thrombosis, transient ischemic attack or myocardial infarction), or having a history or complication of venous thrombosis (such as deep vein thrombosis, pulmonary embolism), or using anticoagulants or antiplatelet drugs at the beginning of screening
  • Having a history of severe cardiovascular diseases (such as grade III/IV congestive heart failure, arrhythmia or angina pectoris that increases the risk of thromboembolic events, unstable angina pectoris, having undergone coronary artery stent implantation, angioplasty or coronary artery bypass grafting)
  • Secondary thrombocytopenia caused by autoimmune diseases such as antiphospholipid antibody syndrome, systemic lupus erythematosus, Hashimoto's thyroiditis, Even's syndrome and Sjogren's syndrome
  • Having a history of severe drug allergic reactions or being known to be allergic to glucocorticoids or Nplate® (romiplostim) or the components of QL0911
  • Having received any Chinese herbal medicine or nutritional supplement (except vitamin supplements and mineral supplements) for the purpose of increasing platelets within 1 week before the first administration
  • Positive results for either human immunodeficiency virus antibody or syphilis antibody screening; positive hepatitis C antibody and HCV-RNA exceeding the upper limit of the study center's laboratory test; positive hepatitis B surface antigen and HBV-DNA exceeding the upper limit of the study center's laboratory test
  • Having undergone splenectomy before the first administration
  • Being pregnant or lactating, or having a pregnancy plan
  • Having fertility and being judged by the researcher as not fully adopting contraceptive measures
  • Unable to comply for mental reasons
  • Judged by the researcher as not suitable to participate in this trial

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 75 év között vagy?

Helyszínek itt: Kína

  • Chinese Academy of Medical Science and Blood Disease HospitalTianjin, KínaContact: Yunfei ChenRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This prospective, multicenter, randomized study aim to evaluate the efficacy and safety of romiplostim N01 combined with glucocorticoids as the first-line treatment for newly diagnosed adult primary immune thrombocytopenia (ITP).

A vizsgálat 2 csoportja

  • romiplostim N01 combined with glucocorticoidsA vizsgált kezelés

    Kezelés: Romiplostim N01 combined with dexamethasone

  • glucocorticoidsMár használt kezelés, összehasonlításként

    Kezelés: Dexamethasone monotherapy

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia (ITP): A Multicenter, Interventional Trial
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT06992128: ki vehet részt
A regiszteradat frissítve
2025. május 28.